GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by Millennium Management LLC

Millennium Management LLC trimmed its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 50.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,186,869 shares of the company's stock after selling 2,217,634 shares during the quarter. Millennium Management LLC owned approximately 0.57% of GoodRx worth $10,169,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in GDRX. National Bank of Canada FI raised its stake in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after buying an additional 2,151 shares during the period. RPO LLC purchased a new position in GoodRx in the 4th quarter valued at $52,000. Versor Investments LP purchased a new position in GoodRx in the 4th quarter valued at $54,000. Verus Capital Partners LLC purchased a new position in GoodRx in the 4th quarter valued at $55,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in GoodRx in the 4th quarter valued at $56,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GDRX has been the topic of a number of research reports. The Goldman Sachs Group decreased their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company decreased their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Truist Financial decreased their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, UBS Group cut their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, GoodRx has an average rating of "Moderate Buy" and a consensus price target of $6.55.

GoodRx Stock Up 0.7%

Shares of GDRX traded up $0.03 during midday trading on Thursday, hitting $3.82. The company had a trading volume of 104,763 shares, compared to its average volume of 1,376,442. The company's 50-day simple moving average is $4.33 and its 200-day simple moving average is $4.56. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market capitalization of $1.36 billion, a P/E ratio of -127.17, a P/E/G ratio of 2.46 and a beta of 1.24. GoodRx Holdings, Inc. has a 1 year low of $3.68 and a 1 year high of $9.26.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analysts' expectations of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.08 earnings per share. As a group, sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.